Coherus Gets Goal Date On US Adalimumab Biosimilar

Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target

 
• By David Wallace
  
Calendar 2021
Coherus has received a goal date from the FDA • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products